Who is eligible?

Patients must meet all of the following criteria to be eligible:

- Patient is of African ancestry including those who self-identify as Black, African American, African or Afro-Caribbean.
- Patient has a diagnosis of non-diabetic chronic kidney disease.
- Patient has not had a kidney transplant.
- Patient has no history of dialysis.

Geographic limitations may apply.

Why test?

A definitive diagnosis of *APOL1*-mediated kidney disease (AMKD) can better inform patient management to:

- Provide a clearer prognosis.
- Guide your treatment decisions.[4]
- Open up potential clinical trial options.[1,2]
- Motivate patients to live a healthier lifestyle and empower decisions.[1]
- Help families understand other family members' risk.[1]
- Provide additional genetic counseling, support and resources.

Learn about the no-cost* Labcorp *APOL1 Genotyping Program*

Visit **LabcorpAPOL1Test.com**

Program support

Our Clinical Program Coordinator can help guide you through setup and testing.

Stephanie Wilson
Clinical Program Coordinator
info@LabcorpAPOL1Test.com
855-610-6115

References:

1. Freedman BI, Burke W, Divers J, et al. Diagnosis, education, and care of patients with *APOL1*-associated nephropathy: a Delphi consensus and systematic review. *J Am Soc Nephrol.* 2021;32(7):1765-1778. doi:10.1681/ASN.2020101399
2. Friedman DJ, Pollak MR. *APOL1* and Kidney Disease: From Genetics to Biology. *Annu Rev Physiol.* 2020 Feb 10;82:323-342. doi: 10.1146/annurev-physiol-021119-034345. Epub 2019 Nov 11. PMID: 31710572.
3. Elliott MD, Marasa M, Cocchi E, et al. Clinical and genetic characteristics of CKD patients with high-risk *APOL1* genotypes. *J Am Soc Nephrol.* 2023;34(5):909-919. doi:10.1681/ASN.0000000000000094.
4. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. *Kidney Int.* 2021;100(4):753-779. doi:10.1016/j.kint.2021.05.015.

labcorp

*Vertex Pharmaceuticals is sponsoring this *APOL1 Genotyping Program* in collaboration with Labcorp, who will perform *APOL1* genotyping and make genetic counseling available for eligible patients at no cost. Program is subject to change or discontinuation without notice. Additional terms and conditions apply.

Participating patients, as well as their treating health care providers, are not required to order, purchase, prescribe and/or obtain any other product or service from Vertex Pharmaceuticals, Labcorp or any of their affiliates.

Please visit LabcorpAPOL1Test.com for more information.

HEALTHCARE PROVIDER'S GUIDE

APOL1 Genotyping Program

A new patient program providing no-cost* genotyping to eligible patients who are at risk for *APOL1*-mediated kidney disease (AMKD).

labcorp

Vertex Pharmaceuticals is sponsoring this *APOL1 Genotyping Program* in collaboration with Labcorp, who will perform *APOL1* genotyping and make genetic counseling available for eligible patients at no cost. Please see back for more information.

What is *APOL1*-mediated kidney disease (AMKD)?

AMKD is a rapidly progressive form of proteinuric non-diabetic kidney disease.[1] It is caused by two risk variants of the *APOL1* gene and a "second hit" (such as infection or inflammation).[2]

What is the Labcorp *APOL1 Genotyping Program*?

This program uses a single-gene test to help inform patients of their risk of a genetic form of kidney disease, AMKD.

Testing of the *APOL1* gene can provide better understanding of patient risk, allowing those with AMKD to learn more about their disease and access genetic counseling. By making a diagnosis at the molecular level, providers have the opportunity to offer patients more information about their kidney disease.

An urgent genetic kidney condition

In the United States, African Americans account for an estimated 35% of all kidney failure cases.[1] Additionally, an estimated 13% of African Americans have two of the *APOL1* genetic variations.[2]

Patients with two risk variants progress to kidney failure 7-9 years earlier than patients without.[3]

Learning more about a little-known disease is the first step toward appropriate treatment options. Getting *APOL1* genotyping results can help inform disease management.

Increasing health equity

This test can help your patients of African ancestry* take a step towards a better understanding of a disease that threatens the health of their community. Additional information about AMKD could lay the groundwork for more equitable healthcare and treatments options in the future.

*To be eligible for this program, patients must be of African ancestry including those who self-identify as Black, African American, African or Afro-Caribbean and have a diagnosis of non-diabetic chronic kidney disease and no history of kidney transplant or dialysis. Geographic limitations may apply. Visit LabcorpAPOL1Test.com for more information.

Patients with two risk variants progress to kidney failure 7-9 years earlier than patients without.[3]

How to participate

1. Sign up
2. Order test
3. Get results

Ready to learn more?

Already have patients that may be eligible for this program?

Visit **LabcorpAPOL1Test.com**

Program support

Our Clinical Program Coordinator can help guide you through setup and testing.

Stephanie Wilson
Clinical Program Coordinator
info@LabcorpAPOL1Test.com
855-610-6115